Other languages REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
16.19 ^USD	+0.81%		+3.19%	-9.81%

Mar. 28	REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD	CI
Mar. 18	Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD	Mar. 28
Regenxbio Insider Sold Shares Worth $365,220, According to a Recent SEC Filing	Mar. 08
Regenxbio Plans to Sell $125 Million in Equity Offering	Mar. 06
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Mar. 05
Sector Update: Health Care	Mar. 05
Regenxbio Reports Higher Microdystrophin Expression in Phase 1/2 Duchenne Study	Mar. 05
REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial	Mar. 05
REGENXBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
REGENXBIO Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Sector Update: Health Care Stocks Firmer Late Afternoon	Feb. 07
Sector Update: Health Care	Feb. 07
Regenxbio Shares Jump Following Clinical Trial Results	Feb. 07
REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint	Feb. 07
REGENXBIO Inc Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in Duchenne Trial	Feb. 07
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05
REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery	Jan. 16
Regenxbio Insider Sold Shares Worth $299,789, According to a Recent SEC Filing	Jan. 04
Regenxbio Insider Sold Shares Worth $885,825, According to a Recent SEC Filing	Dec. 21
Regenxbio Begins Dose Escalation in Trial of Duchenne Muscular Dystrophy Therapy	Nov. 29
REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial	Nov. 29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages REGENXBIO Inc.

Equities

RGNX

US75901B1070

Other languages

Filters